Q&A with Dr. Gregory Carter: Developing Computational Strategies and the MODEL-AD Consortium

Gregory Carter, Ph.D., is an Associate Professor at The Jackson Laboratory. His work is focused on developing computational strategies using genetic data to understand complex genetic systems. We recently spoke with Dr. Carter about his research and the MODEL-AD consortium....

Meta-analysis of AMP-AD Datasets Defines the Transcriptional Landscape of Alzheimer’s Disease

The Accelerating Medicines Partnership - Alzheimer’s Disease (AMP-AD) Consortium was formed to accelerate the development of diagnostics and therapeutics for this devastating and complex disease. One roadblock to development is the lack of good pre-clinical models, as efficacy in clinical...

/ January 31, 2019

NanoString-based publications 2018: A year in review

2018 was an incredibly productive year for scientific publications showcasing the NanoString platform and assays. We added nearly 500 publications of various scientific disciplines which are available on our website here. Below are some of the highlights of the year. It’s...

/ January 21, 2019

Q&A with Dr. Juliane Nguyen: Exosome Profiling with miRNA and Biotech’s Next Breakthrough

Dr. Juliane Nguyen is a professor in the Department of Pharmaceutical Sciences at the University of Buffalo. Her Therapeutic Biomaterials Laboratory investigates using exosomes and other nanoscale carriers for the treatment of diseases including cancer and ischemic heart disease. NanoString...

The Votes Are In- What Causes qPCR and RNA-Seq Variability?

Retraction. A word feared by every scientist conducting lab experiments and publishing data. I came across an interesting article recently entitled “Sources of error in the retracted scientific literature” (Arturo Casadevall et. al.). The paper noted that retraction of flawed...

/ November 7, 2018